JP2010043089A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010043089A5 JP2010043089A5 JP2009211917A JP2009211917A JP2010043089A5 JP 2010043089 A5 JP2010043089 A5 JP 2010043089A5 JP 2009211917 A JP2009211917 A JP 2009211917A JP 2009211917 A JP2009211917 A JP 2009211917A JP 2010043089 A5 JP2010043089 A5 JP 2010043089A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- hngf
- human
- agent
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108010025020 Nerve Growth Factor Proteins 0.000 claims description 15
- 102000015336 Nerve Growth Factor Human genes 0.000 claims description 15
- 101150111783 NTRK1 gene Proteins 0.000 claims description 12
- 101710187830 Tumor necrosis factor receptor superfamily member 1B Proteins 0.000 claims description 7
- 208000004454 Hyperalgesia Diseases 0.000 claims description 6
- 208000035154 Hyperesthesia Diseases 0.000 claims description 6
- 230000000694 effects Effects 0.000 claims description 6
- 238000001727 in vivo Methods 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims 18
- 239000008194 pharmaceutical composition Substances 0.000 claims 17
- 239000003814 drug Substances 0.000 claims 15
- 208000027866 inflammatory disease Diseases 0.000 claims 14
- 201000010099 disease Diseases 0.000 claims 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 11
- 208000002193 Pain Diseases 0.000 claims 10
- 206010003246 arthritis Diseases 0.000 claims 8
- 230000002401 inhibitory effect Effects 0.000 claims 8
- 201000004681 Psoriasis Diseases 0.000 claims 7
- 208000006673 asthma Diseases 0.000 claims 7
- 229940079593 drug Drugs 0.000 claims 7
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 6
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 6
- 206010025135 lupus erythematosus Diseases 0.000 claims 5
- 201000006417 multiple sclerosis Diseases 0.000 claims 5
- 208000011231 Crohn disease Diseases 0.000 claims 4
- 201000004624 Dermatitis Diseases 0.000 claims 4
- 206010012442 Dermatitis contact Diseases 0.000 claims 4
- 208000007514 Herpes zoster Diseases 0.000 claims 4
- 101000736088 Homo sapiens PC4 and SFRS1-interacting protein Proteins 0.000 claims 4
- 101000801254 Homo sapiens Tumor necrosis factor receptor superfamily member 16 Proteins 0.000 claims 4
- 101000801232 Homo sapiens Tumor necrosis factor receptor superfamily member 1B Proteins 0.000 claims 4
- 206010036376 Postherpetic Neuralgia Diseases 0.000 claims 4
- 208000010668 atopic eczema Diseases 0.000 claims 4
- 206010009887 colitis Diseases 0.000 claims 4
- 208000010247 contact dermatitis Diseases 0.000 claims 4
- 201000003146 cystitis Diseases 0.000 claims 4
- 102000052073 human NGFR Human genes 0.000 claims 4
- 210000000987 immune system Anatomy 0.000 claims 4
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 4
- 238000004519 manufacturing process Methods 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 3
- 229940124597 therapeutic agent Drugs 0.000 claims 3
- KUVIULQEHSCUHY-XYWKZLDCSA-N Beclometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O KUVIULQEHSCUHY-XYWKZLDCSA-N 0.000 claims 2
- 208000000094 Chronic Pain Diseases 0.000 claims 2
- 101001111439 Homo sapiens Beta-nerve growth factor Proteins 0.000 claims 2
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 claims 2
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 claims 2
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 claims 2
- 101100404651 Mus musculus Ngf gene Proteins 0.000 claims 2
- 102100033733 Tumor necrosis factor receptor superfamily member 1B Human genes 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 claims 2
- 229950000210 beclometasone dipropionate Drugs 0.000 claims 2
- 239000003246 corticosteroid Substances 0.000 claims 2
- 102000046917 human NGF Human genes 0.000 claims 2
- 102000057041 human TNF Human genes 0.000 claims 2
- 208000011580 syndromic disease Diseases 0.000 claims 2
- 108091008604 NGF receptors Proteins 0.000 claims 1
- 102000007339 Nerve Growth Factor Receptors Human genes 0.000 claims 1
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 229940125644 antibody drug Drugs 0.000 claims 1
- 239000003446 ligand Substances 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 102000003298 tumor necrosis factor receptor Human genes 0.000 claims 1
- 102100036220 PC4 and SFRS1-interacting protein Human genes 0.000 description 5
- 230000003993 interaction Effects 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29439201P | 2001-05-30 | 2001-05-30 | |
| US60/294,392 | 2001-05-30 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002592967A Division JP4567944B2 (ja) | 2001-05-30 | 2002-05-09 | 種々の疾患の治療のための抗−ｎｇｆ抗体 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013025893A Division JP2013139453A (ja) | 2001-05-30 | 2013-02-13 | 種々の疾患の治療のための抗−ｎｇｆ抗体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010043089A JP2010043089A (ja) | 2010-02-25 |
| JP2010043089A5 true JP2010043089A5 (enExample) | 2012-10-25 |
| JP5761902B2 JP5761902B2 (ja) | 2015-08-12 |
Family
ID=23133215
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002592967A Expired - Lifetime JP4567944B2 (ja) | 2001-05-30 | 2002-05-09 | 種々の疾患の治療のための抗−ｎｇｆ抗体 |
| JP2009211917A Expired - Lifetime JP5761902B2 (ja) | 2001-05-30 | 2009-09-14 | 種々の疾患の治療のための抗−ｎｇｆ抗体 |
| JP2013025893A Withdrawn JP2013139453A (ja) | 2001-05-30 | 2013-02-13 | 種々の疾患の治療のための抗−ｎｇｆ抗体 |
| JP2014215231A Pending JP2015061840A (ja) | 2001-05-30 | 2014-10-22 | 種々の疾患の治療のための抗−ｎｇｆ抗体 |
| JP2016079748A Expired - Lifetime JP6271631B2 (ja) | 2001-05-30 | 2016-04-12 | 種々の疾患の治療のための抗−ｎｇｆ抗体 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002592967A Expired - Lifetime JP4567944B2 (ja) | 2001-05-30 | 2002-05-09 | 種々の疾患の治療のための抗−ｎｇｆ抗体 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013025893A Withdrawn JP2013139453A (ja) | 2001-05-30 | 2013-02-13 | 種々の疾患の治療のための抗−ｎｇｆ抗体 |
| JP2014215231A Pending JP2015061840A (ja) | 2001-05-30 | 2014-10-22 | 種々の疾患の治療のための抗−ｎｇｆ抗体 |
| JP2016079748A Expired - Lifetime JP6271631B2 (ja) | 2001-05-30 | 2016-04-12 | 種々の疾患の治療のための抗−ｎｇｆ抗体 |
Country Status (18)
| Country | Link |
|---|---|
| US (7) | US7727527B2 (enExample) |
| EP (2) | EP1401498B1 (enExample) |
| JP (5) | JP4567944B2 (enExample) |
| KR (3) | KR101004353B1 (enExample) |
| CN (2) | CN101653604A (enExample) |
| AT (1) | ATE522229T1 (enExample) |
| AU (7) | AU2002308722B2 (enExample) |
| BR (1) | BR0210231A (enExample) |
| CA (2) | CA2975521A1 (enExample) |
| CY (1) | CY1112425T1 (enExample) |
| DK (1) | DK1401498T3 (enExample) |
| ES (1) | ES2371748T3 (enExample) |
| IL (2) | IL158921A0 (enExample) |
| MX (1) | MXPA03010911A (enExample) |
| NZ (2) | NZ544410A (enExample) |
| PT (1) | PT1401498E (enExample) |
| WO (1) | WO2002096458A1 (enExample) |
| ZA (1) | ZA200308999B (enExample) |
Families Citing this family (73)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2002308722B2 (en) * | 2001-05-30 | 2007-05-17 | Genentech, Inc. | Anti-NGF antibodies for the treatment of various disorders |
| WO2004032870A2 (en) | 2002-10-08 | 2004-04-22 | Rinat Neuroscience Corp. | Methods for treating post-surgical pain by admisnistering a nerve growth factor antagonist and compositions containing the same |
| US7255860B2 (en) | 2002-10-08 | 2007-08-14 | Rinat Neuroscience Corp. | Methods for treating post-surgical pain by administering an anti-nerve growth factor antagonist antibody |
| UA80447C2 (en) | 2002-10-08 | 2007-09-25 | Methods for treating pain by administering nerve growth factor antagonist and opioid analgesic | |
| US9498530B2 (en) | 2002-12-24 | 2016-11-22 | Rinat Neuroscience Corp. | Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same |
| SI2270048T1 (sl) * | 2002-12-24 | 2016-01-29 | Rinat Neuroscience Corp. | Protitelesa proti NGF-ju in postopki uporabe le-teh |
| US7569364B2 (en) | 2002-12-24 | 2009-08-04 | Pfizer Inc. | Anti-NGF antibodies and methods using same |
| AU2011201157C1 (en) * | 2002-12-24 | 2017-09-07 | Rinat Neuroscience Corp. | Anti-NGF antibodies and methods using same |
| US7655231B2 (en) * | 2003-02-19 | 2010-02-02 | Pfizer Inc. | Methods for treating pain by administering a nerve growth factor antagonist and an NSAID |
| KR100894191B1 (ko) | 2003-07-15 | 2009-04-22 | 암젠 인코포레이티드 | 선택적인 ｎｇｆ 경로 저해제로서의 인체 항-ｎｇｆ 중화 항체 및 이 항체를 포함하는 약학적 조성물 |
| NZ588527A (en) * | 2003-07-15 | 2012-06-29 | Amgen Inc | Human anti-NGF neutralizing antibodies as selective NGF pathway inhibitors |
| ITRM20030601A1 (it) | 2003-12-24 | 2005-06-25 | Lay Line Genomics Spa | Metodo per l'umanizzazione di anticorpi e anticorpi umanizzati con esso ottenuti. |
| SG152226A1 (en) * | 2004-04-07 | 2009-05-29 | Rinat Neuroscience Corp | Methods for treating bone cancer pain by administering a nerve growth factor antagonist |
| ME00226B (me) | 2004-07-15 | 2011-02-10 | Medarex Llc | Humana anti-ngf neutrališuća antitijela kao selektivni inhibitori ngf signalne kaskade |
| CN101107268B (zh) * | 2005-01-24 | 2012-06-27 | 剑桥抗体技术有限公司 | 针对ngf的特异性结合成员 |
| ITRM20050290A1 (it) | 2005-06-07 | 2006-12-08 | Lay Line Genomics Spa | Uso di molecole in grado di inibire il legame tra ngf e il suo recettore trka come analgesici ad effetto prolungato. |
| EP1857146A1 (en) * | 2006-05-16 | 2007-11-21 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Treatment of respiratory disorders |
| NZ579010A (en) | 2007-02-20 | 2012-03-30 | Anaptysbio Inc | Somatic hypermutation systems |
| BRPI0815370B8 (pt) | 2007-08-10 | 2021-05-25 | Regeneron Pharma | anticorpos humanos de alta afinidade contra o fator de crescimento neural humano e seu uso, molécula de ácido nucleico, vetor de expressão, método para produção de um anticorpo anti-ngf humano e composiçao farmacêutica |
| US8309088B2 (en) | 2007-08-10 | 2012-11-13 | Regeneron Pharmaceuticals, Inc. | Method of treating osteoarthritis with an antibody to NGF |
| CN102216329A (zh) * | 2007-12-17 | 2011-10-12 | 辉瑞有限公司 | 间质性膀胱炎的治疗 |
| NZ588554A (en) * | 2008-04-29 | 2013-03-28 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
| AU2009256250B2 (en) | 2008-06-03 | 2013-05-30 | Abbvie Inc. | Dual variable domain immunoglobulins and uses thereof |
| SG191625A1 (en) | 2008-06-03 | 2013-07-31 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
| SG192489A1 (en) * | 2008-07-08 | 2013-08-30 | Abbott Lab | Prostaglandin e2 dual variable domain immunoglobulins and uses thereof |
| PT2350075E (pt) | 2008-09-22 | 2014-06-09 | Array Biopharma Inc | Compostos imidazo[1,2b]piridazina substituídos como inibidores da trk cinase |
| ME03010B (me) | 2008-10-22 | 2018-10-20 | Array Biopharma Inc | Jedinjenja supstituisanog pirazol0[1,5-]pirimidina као inhibitori trk kinaze |
| AU2010242840B2 (en) * | 2009-05-01 | 2014-04-17 | Abbvie Inc. | Dual variable domain immunoglobulins and uses thereof |
| MX2011011728A (es) | 2009-05-04 | 2012-04-19 | Abbott Res Bv | Anticuerpos contra el factor de crecimiento nervioso (ngf) con estabilidad in vivo mejorada. |
| AR077468A1 (es) | 2009-07-09 | 2011-08-31 | Array Biopharma Inc | Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa |
| CN102612524A (zh) * | 2009-09-01 | 2012-07-25 | 雅培制药有限公司 | 双重可变结构域免疫球蛋白及其用途 |
| PH12012500691A1 (en) * | 2009-10-15 | 2012-11-12 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
| UY32979A (es) * | 2009-10-28 | 2011-02-28 | Abbott Lab | Inmunoglobulinas con dominio variable dual y usos de las mismas |
| EP2547365A1 (en) | 2010-03-17 | 2013-01-23 | Abbott Research B.V. | Anti-nerve growth factor (ngf) antibody compositions |
| PL2918588T3 (pl) | 2010-05-20 | 2017-10-31 | Array Biopharma Inc | Związki makrocykliczne jako inhibitory kinazy TRK |
| MX341579B (es) | 2010-08-03 | 2016-08-25 | Abbvie Inc * | Inmunoglobulinas de dominio variable doble y usos de las mismas. |
| AU2015258217A1 (en) * | 2010-08-19 | 2015-12-03 | Zoetis Belgium S.A. | Anti-NGF antibodies and their use |
| EP3333188B1 (en) * | 2010-08-19 | 2022-02-09 | Zoetis Belgium S.A. | Anti-ngf antibodies and their use |
| TW201211252A (en) * | 2010-08-26 | 2012-03-16 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
| US11214610B2 (en) | 2010-12-01 | 2022-01-04 | H. Lundbeck A/S | High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris |
| US9539324B2 (en) | 2010-12-01 | 2017-01-10 | Alderbio Holdings, Llc | Methods of preventing inflammation and treating pain using anti-NGF compositions |
| US9884909B2 (en) | 2010-12-01 | 2018-02-06 | Alderbio Holdings Llc | Anti-NGF compositions and use thereof |
| US9078878B2 (en) | 2010-12-01 | 2015-07-14 | Alderbio Holdings Llc | Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75 |
| CN103619879A (zh) | 2010-12-01 | 2014-03-05 | 奥尔德生物控股有限责任公司 | 抗ngf组合物及其用途 |
| US9067988B2 (en) | 2010-12-01 | 2015-06-30 | Alderbio Holdings Llc | Methods of preventing or treating pain using anti-NGF antibodies |
| ITRM20110024A1 (it) * | 2011-01-24 | 2012-07-25 | Consiglio Nazionale Ricerche | Uso di antagonisti del recettore p75ntr e/o di agonisti del recettore trka per il trattamento delle malattie infiammatorie croniche. |
| HRP20180155T1 (hr) | 2011-08-11 | 2018-03-23 | Astellas Pharma Inc. | Novo protutijelo protiv ljudskog ngf |
| US8926978B2 (en) | 2011-10-25 | 2015-01-06 | Anaptysbio, Inc. | Antibodies directed against nerve growth factor (NGF) |
| BR112014015851A2 (pt) | 2011-12-30 | 2019-09-24 | Abbvie Inc | proteínas de ligação específicas duplas direcionadas contra il-13 e/ou il-17 |
| US9617334B2 (en) | 2012-06-06 | 2017-04-11 | Zoetis Services Llc | Caninized anti-NGF antibodies and methods thereof |
| PE20151179A1 (es) | 2012-11-01 | 2015-09-12 | Abbvie Inc | Inmunoglobulinas de dominio variable dual anti-vegf/dll4 y usos de las mismas |
| US9127055B2 (en) | 2013-02-08 | 2015-09-08 | Astellas Pharma Inc. | Method of treating pain with anti-human NGF antibody |
| JP2016522793A (ja) | 2013-03-15 | 2016-08-04 | アッヴィ・インコーポレイテッド | ＩＬ−１βおよび／またはＩＬ−１７に対して指向された二重特異的結合タンパク質 |
| EP3099713B1 (en) | 2014-02-02 | 2020-01-15 | MedImmune Limited | Chimeric protein composed of ngf antagonist domain and a tnfa antagonist domain |
| TWI767858B (zh) | 2014-11-16 | 2022-06-11 | 美商亞雷生物製藥股份有限公司 | (S)-N-(5-((R)-2-(2,5-二氟苯基)-吡咯啶-1-基)-吡唑并[1,5-a]嘧啶-3-基)-3-羥基吡咯啶-1-甲醯胺硫酸氫鹽結晶型 |
| WO2016094881A2 (en) | 2014-12-11 | 2016-06-16 | Abbvie Inc. | Lrp-8 binding proteins |
| TW201710286A (zh) | 2015-06-15 | 2017-03-16 | 艾伯維有限公司 | 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白 |
| CA3003153A1 (en) | 2015-10-26 | 2017-05-04 | Loxo Oncology, Inc. | Point mutations in trk inhibitor-resistant cancer and methods relating to the same |
| US10045991B2 (en) | 2016-04-04 | 2018-08-14 | Loxo Oncology, Inc. | Methods of treating pediatric cancers |
| DK3439662T3 (da) | 2016-04-04 | 2024-09-02 | Loxo Oncology Inc | Væskeformige formuleringer af (s)-n-(5-((r)-2-(2,5-difluorphenyl)-pyrrolidin-1-yl)-pyrazol[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidin-1-carboxamid |
| EP3458456B1 (en) | 2016-05-18 | 2020-11-25 | Loxo Oncology Inc. | Preparation of (s)-n-(5-((r)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide |
| JOP20190092A1 (ar) | 2016-10-26 | 2019-04-25 | Array Biopharma Inc | عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها |
| JOP20190213A1 (ar) | 2017-03-16 | 2019-09-16 | Array Biopharma Inc | مركبات حلقية ضخمة كمثبطات لكيناز ros1 |
| US20180357486A1 (en) * | 2017-06-07 | 2018-12-13 | Satori Worldwide, Llc | System and method for analyzing video frames in a messaging system |
| BR112020017701A2 (pt) | 2018-03-12 | 2020-12-29 | Zoetis Services Llc | Anticorpos anti-ngf e métodos dos mesmos |
| CN108743568B (zh) * | 2018-06-05 | 2021-09-07 | 桂林医学院附属医院 | 用于降低气道高反应性的抗ngf抗体缓释微球及制备方法 |
| CN112625128B (zh) * | 2020-08-06 | 2022-11-08 | 熙源安健医药（上海）有限公司 | 抗ngf抗体及其抗原结合片段、其制备方法和应用 |
| AU2021350424A1 (en) | 2020-09-28 | 2023-06-01 | Medimmune Limited | Compounds and methods for treating pain |
| JP2023544839A (ja) | 2020-10-07 | 2023-10-25 | ゾエティス・サービシーズ・エルエルシー | 抗ｎｇｆ抗体及びその使用方法 |
| US20250346657A1 (en) | 2021-12-16 | 2025-11-13 | Intervet Inc. | Caninized and felinized antibodies to human ngf |
| US20230348608A1 (en) | 2022-04-27 | 2023-11-02 | Regeneron Pharmaceuticals, Inc. | Treatment Of Arthropathy Based Upon Stratification Of Osteoarthritis Polygenic Risk Score |
| US20240310383A1 (en) | 2023-03-17 | 2024-09-19 | Regeneron Pharmaceuticals, Inc. | Proteomic Risk Score For Osteoarthritis (OA) |
| WO2025264860A2 (en) | 2024-06-18 | 2025-12-26 | Yale University | Methods of treating post-covid airway disease |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| FR2413974A1 (fr) | 1978-01-06 | 1979-08-03 | David Bernard | Sechoir pour feuilles imprimees par serigraphie |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| US4906476A (en) * | 1988-12-14 | 1990-03-06 | Liposome Technology, Inc. | Novel liposome composition for sustained release of steroidal drugs in lungs |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| DE69029036T2 (de) | 1989-06-29 | 1997-05-22 | Medarex Inc | Bispezifische reagenzien für die aids-therapie |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| CA2097309A1 (en) * | 1990-11-30 | 1992-05-31 | Peter S. Distefano | Immunoassay and monoclonal antibodies useful for detecting truncated nerve growth factor receptor |
| WO1992020373A1 (en) | 1991-05-14 | 1992-11-26 | Repligen Corporation | Heteroconjugate antibodies for treatment of hiv infection |
| AU675916B2 (en) | 1991-06-14 | 1997-02-27 | Genentech Inc. | Method for making humanized antibodies |
| EP0605522B1 (en) | 1991-09-23 | 1999-06-23 | Medical Research Council | Methods for the production of humanized antibodies |
| EP0617706B1 (en) | 1991-11-25 | 2001-10-17 | Enzon, Inc. | Multivalent antigen-binding proteins |
| JP3714683B2 (ja) * | 1992-07-30 | 2005-11-09 | 生化学工業株式会社 | 抗リウマチ剤 |
| ES2153384T3 (es) * | 1993-07-30 | 2001-03-01 | Kennedy Inst Of Rheumatology | Metodo para tratar la esclerosis multiple. |
| US5753225A (en) * | 1993-12-03 | 1998-05-19 | The Regents Of The University Of California | Antibodies that mimic actions of neurotrophins |
| US5728803A (en) * | 1994-06-03 | 1998-03-17 | Genentech, Inc. | Pantropic neurotrophic factors |
| US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
| IT1306704B1 (it) * | 1999-05-26 | 2001-10-02 | Sirs Societa Italiana Per La R | Anticorpi monoclonali e suoi derivati sintetici o biotecnologici ingrado di agire come molecole antagoniste per il ngf. |
| US6548062B2 (en) * | 2000-02-29 | 2003-04-15 | Cephalon, Inc. | Method of treating cancer with anti-neurotrophin agents |
| FR2807660A1 (fr) * | 2000-04-13 | 2001-10-19 | Warner Lambert Co | Utilisation d'antagonistes du ngf pour la prevention ou le traitement de douleurs viscerales chroniques |
| US7220840B2 (en) * | 2000-06-16 | 2007-05-22 | Human Genome Sciences, Inc. | Antibodies that immunospecifically bind to B lymphocyte stimulator protein |
| ATE442862T2 (de) * | 2000-10-12 | 2009-10-15 | Genentech Inc | Niederviskose konzentrierte proteinformulierungen |
| AU2002308722B2 (en) * | 2001-05-30 | 2007-05-17 | Genentech, Inc. | Anti-NGF antibodies for the treatment of various disorders |
| EP1545615A4 (en) * | 2002-10-04 | 2006-03-01 | Rinat Neuroscience Corp | METHODS OF TREATING CARDIAC ARRHYTHMIA AND PREVENTING DEATH OF CARDIAC ARRHYTHMIA USING NGF ANTAGONISTS |
| UA80447C2 (en) * | 2002-10-08 | 2007-09-25 | Methods for treating pain by administering nerve growth factor antagonist and opioid analgesic | |
| US7655231B2 (en) * | 2003-02-19 | 2010-02-02 | Pfizer Inc. | Methods for treating pain by administering a nerve growth factor antagonist and an NSAID |
| SG152226A1 (en) * | 2004-04-07 | 2009-05-29 | Rinat Neuroscience Corp | Methods for treating bone cancer pain by administering a nerve growth factor antagonist |
-
2002
- 2002-05-09 AU AU2002308722A patent/AU2002308722B2/en not_active Expired
- 2002-05-09 CA CA2975521A patent/CA2975521A1/en not_active Abandoned
- 2002-05-09 EP EP02774103A patent/EP1401498B1/en not_active Revoked
- 2002-05-09 KR KR1020087027819A patent/KR101004353B1/ko not_active Expired - Lifetime
- 2002-05-09 KR KR10-2003-7015659A patent/KR20040049829A/ko not_active Ceased
- 2002-05-09 MX MXPA03010911A patent/MXPA03010911A/es not_active Application Discontinuation
- 2002-05-09 CN CN200910171008A patent/CN101653604A/zh active Pending
- 2002-05-09 DK DK02774103.2T patent/DK1401498T3/da active
- 2002-05-09 JP JP2002592967A patent/JP4567944B2/ja not_active Expired - Lifetime
- 2002-05-09 ES ES02774103T patent/ES2371748T3/es not_active Expired - Lifetime
- 2002-05-09 AT AT02774103T patent/ATE522229T1/de active
- 2002-05-09 IL IL15892102A patent/IL158921A0/xx unknown
- 2002-05-09 US US10/479,872 patent/US7727527B2/en not_active Expired - Lifetime
- 2002-05-09 BR BR0210231-5A patent/BR0210231A/pt not_active Application Discontinuation
- 2002-05-09 NZ NZ544410A patent/NZ544410A/en not_active IP Right Cessation
- 2002-05-09 NZ NZ529612A patent/NZ529612A/xx not_active IP Right Cessation
- 2002-05-09 EP EP10010557A patent/EP2340849A1/en not_active Ceased
- 2002-05-09 CN CNA028149920A patent/CN1684708A/zh active Pending
- 2002-05-09 CA CA2448956A patent/CA2448956C/en not_active Expired - Lifetime
- 2002-05-09 WO PCT/US2002/015284 patent/WO2002096458A1/en not_active Ceased
- 2002-05-09 KR KR1020107027004A patent/KR20100132559A/ko not_active Withdrawn
- 2002-05-09 PT PT02774103T patent/PT1401498E/pt unknown
-
2003
- 2003-11-18 IL IL158921A patent/IL158921A/en active IP Right Grant
- 2003-11-19 ZA ZA2003/08999A patent/ZA200308999B/en unknown
-
2007
- 2007-08-16 AU AU2007207881A patent/AU2007207881B2/en not_active Expired
-
2009
- 2009-09-14 JP JP2009211917A patent/JP5761902B2/ja not_active Expired - Lifetime
-
2010
- 2010-01-15 AU AU2010200170A patent/AU2010200170B2/en not_active Expired
- 2010-04-06 US US12/755,279 patent/US20100254990A1/en not_active Abandoned
-
2011
- 2011-04-19 US US13/090,048 patent/US20110268725A1/en not_active Abandoned
- 2011-11-28 CY CY20111101167T patent/CY1112425T1/el unknown
-
2012
- 2012-09-06 US US13/605,722 patent/US20130004495A1/en not_active Abandoned
-
2013
- 2013-02-13 JP JP2013025893A patent/JP2013139453A/ja not_active Withdrawn
- 2013-10-10 AU AU2013242812A patent/AU2013242812A1/en not_active Abandoned
-
2014
- 2014-03-24 US US14/223,881 patent/US20140294829A1/en not_active Abandoned
- 2014-10-22 JP JP2014215231A patent/JP2015061840A/ja active Pending
-
2016
- 2016-04-12 US US15/097,225 patent/US20170066819A1/en not_active Abandoned
- 2016-04-12 JP JP2016079748A patent/JP6271631B2/ja not_active Expired - Lifetime
- 2016-11-03 AU AU2016253605A patent/AU2016253605A1/en not_active Abandoned
-
2018
- 2018-06-04 AU AU2018203920A patent/AU2018203920A1/en not_active Abandoned
-
2020
- 2020-05-11 US US16/871,525 patent/US20200399357A1/en not_active Abandoned
- 2020-05-12 AU AU2020203115A patent/AU2020203115A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010043089A5 (enExample) | ||
| JP2004536072A5 (enExample) | ||
| JP5537740B2 (ja) | Ｉｌ−１７アンタゴニストを用いて乾癬を治療する方法 | |
| JP7736667B2 (ja) | Ｉｌ－４ｒアンタゴニストを投与することによるアトピー性皮膚炎の治療方法 | |
| JP2022023051A (ja) | 瘻孔を伴うクローン病の治療用ベドリズマブ | |
| CN112969719A (zh) | 双功能融合蛋白及其医药用途 | |
| JP7766392B2 (ja) | 治療用抗ｃｄ４０リガンド抗体 | |
| CN105392803B (zh) | C5aR拮抗剂的用途 | |
| CN117222663A (zh) | 使用结合nkg2d、cd16和肿瘤相关抗原的多特异性结合蛋白治疗癌症的方法 | |
| JP2013539352A5 (enExample) | ||
| CA3207818A1 (en) | Anti-tl1a antibody compositions and methods of treatment in the lung | |
| KR20140015139A (ko) | 이원 가변 도메인 면역글로불린 및 이의 용도 | |
| KR20130100118A (ko) | 이원 가변 도메인 면역글로불린 및 이의 용도 | |
| CN103189074A (zh) | 使用il-17拮抗剂治疗类风湿性关节炎的方法 | |
| JP2023520676A (ja) | Ｉｌ－４ｒアンタゴニストを投与することによりアトピー性皮膚炎を処置するための方法 | |
| JP2019206535A (ja) | Ｉｌ−１７アンタゴニストを使用して汎発性膿疱性乾癬（ｇｐｐ）を処置する方法 | |
| JP2022512722A (ja) | 抗ｃｄ３８抗体の皮下投与を提供する方法 | |
| JP2019515676A5 (enExample) | ||
| AU2018369986A1 (en) | Treating Hidradenitis suppurativa with IL-17 antagonists | |
| CA3207817A1 (en) | Compositions comprising humanized antibodies to tnf-like ligand 1a (tl1a) and uses thereof | |
| JP2025102888A (ja) | Ｉｌ－１７アンタゴニストを用いて初発プラーク型乾癬を治療する方法 | |
| JP2021119168A (ja) | 抗ｉｌ−１７ａ／ｆ抗体を用いた治療方法 | |
| JP7572041B2 (ja) | 重症喘息を処置するための組成物および方法 | |
| TW202332691A (zh) | Ige調節的疾病的治療 | |
| JP6663910B2 (ja) | 抗ＴＮＦ−α抗体療法を受けた乾癬患者を治療するための方法 |